Medicaid Access to Parenteral Nutrition
SB084 concerns Medicaid coverage for parenteral nutrition, a specialized form of intravenous nutrition used by patients who cannot absorb food through the gastrointestinal tract. The bill’s legislative declaration states that parenteral nutrition can be life-sustaining, especially for children and other patients with severe feeding and digestion disabilities, and that infusion pharmacies face high costs and operational burdens in preparing these products. It also notes concerns that some pharmacies nationwide have stopped supplying parenteral nutrition because of financial pressure, creating access problems for Medicaid members.
The bill directs the state Department of Health Care Policy and Financing, once any needed federal approval is obtained, to create specific professional dispensing fees for the preparation and dispensing of parenteral nutrition beginning on or before January 1, 2026. Those fees are intended to encourage enough infusion pharmacies to participate in the Medicaid program, and during the first year they may not exceed 30% of infusion pharmacy administrative costs for this service. The department must also seek federal authorization as needed to implement the fee structure.
SB084 further requires annual reporting to the Joint Budget Committee and the SMART Act hearing beginning November 1, 2026. The report must include the number and geographic distribution of infusion pharmacies serving parenteral nutrition patients, the number of new participating pharmacies, separate data on adult and child needs, and any reimbursement or regulatory changes made to improve market participation. The bill includes a general fund appropriation of $54,832 for fiscal year 2025-26 and anticipates matching federal funds of the same amount.
The bill’s impact is to amend Colorado Medicaid law by creating a targeted reimbursement mechanism for a narrow but medically critical service and by adding ongoing oversight requirements. It affects the Department of Health Care Policy and Financing, Medicaid providers, and infusion pharmacies that prepare parenteral nutrition, with the goal of improving network adequacy and patient access to medically necessary nutrition support.
The overall sentiment appears strongly supportive and largely noncontroversial. The bill advanced through both chambers with unanimous or near-unanimous committee votes, and the Senate later concurred with House amendments without opposition. The only notable contention reflected in the voting history was a small number of no votes in House Appropriations and on House third reading, suggesting limited concern, likely around fiscal or implementation details rather than the bill’s core purpose. The amendments adopted in committee indicate the measure was refined during the process, but the final trajectory was broadly favorable.
SB084 adds a new Medicaid reimbursement and reporting section to Colorado law, requiring the state department to establish specific professional dispensing fees for parenteral nutrition if federal approval is obtained. It also imposes annual reporting obligations on network adequacy, pharmacy participation, and reimbursement changes, and appropriates state and anticipated federal funds to implement the measure. The bill primarily affects Medicaid administration, infusion pharmacies, and Medicaid members who rely on parenteral nutrition, especially children and other medically fragile patients.
The bill appears to have enjoyed broad bipartisan support and little public controversy in the recorded votes. It passed Senate and House committees overwhelmingly, cleared both chambers, and the Senate concurred in House amendments unanimously. The few dissenting votes in House Appropriations and House third reading suggest some limited concern, but the overall sentiment was positive and focused on improving access to medically necessary care.
The main policy issue is whether current Medicaid reimbursement is sufficient to keep enough infusion pharmacies in the market to provide parenteral nutrition. Supporters argue that higher or more targeted dispensing fees are needed to maintain access, while any opposition appears to have centered on fiscal cost, administrative implementation, or the need for federal approval before the fee structure can take effect. The bill’s requirement that fees not exceed 30% of administrative costs in the first year reflects an attempt to balance provider participation with cost control.